Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Edwards Lifesciences Corporation
Edwards Lifesciences Corporation News
Aug 14, 2025 - globenewswire.com
Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm
Aug 13, 2025 - globenewswire.com
EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Edwards Lifesciences Corporation Quantitative Score
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Edwards Lifesciences Corporation Financials
Table Compare
Compare EW metrics with: | |||
|---|---|---|---|
Earnings & Growth | EW | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EW | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EW | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EW | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Edwards Lifesciences Corporation Income
Edwards Lifesciences Corporation Balance Sheet
Edwards Lifesciences Corporation Cash Flow
Edwards Lifesciences Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Edwards Lifesciences Corporation Executives
| Name | Role |
|---|---|
| Mr. Bernard J. Zovighian | Chief Executive Officer & Director |
| Mr. Larry L. Wood | Corporate Vice President and Group President of TAVR & Surgical Structural Heart |
| Mr. Jean-Luc Lemercier | Corporate Vice President of Japan, Asia Pacific & Greater China |
| Mr. Scott B. Ullem | Corporate Vice President & Chief Financial Officer |
| Mr. Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Bernard J. Zovighian | Chief Executive Officer & Director | Male | 1968 | 2.68M |
| Mr. Larry L. Wood | Corporate Vice President and Group President of TAVR & Surgical Structural Heart | Male | 1966 | 1.51M |
| Mr. Jean-Luc Lemercier | Corporate Vice President of Japan, Asia Pacific & Greater China | Male | 1957 | 1.43M |
| Mr. Scott B. Ullem | Corporate Vice President & Chief Financial Officer | Male | 1967 | 1.37M |
| Mr. Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development | Male | 1962 | 1.37M |
Edwards Lifesciences Corporation Insider Trades
| Date | 28 Jul |
| Name | Lippis Daniel J. |
| Role | CVP, JAPAC |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 4114 |
| Date | 11 Jul |
| Name | Bruls Annette |
| Role | CVP, EMEACLA |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 109 |
| Date | 7 Jul |
| Name | Lippis Daniel J. |
| Role | CVP, JAPAC |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 333 |
| Date | 16 Jun |
| Name | Wood Larry L |
| Role | Global President TAVR & Surg |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 8950 |
| Date | 16 Jun |
| Name | Wood Larry L |
| Role | Global President TAVR & Surg |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 8950 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 28 Jul | Lippis Daniel J. | CVP, JAPAC | Disposed | S-Sale | 4114 |
| 11 Jul | Bruls Annette | CVP, EMEACLA | Disposed | F-InKind | 109 |
| 7 Jul | Lippis Daniel J. | CVP, JAPAC | Disposed | F-InKind | 333 |
| 16 Jun | Wood Larry L | Global President TAVR & Surg | Acquired | M-Exempt | 8950 |
| 16 Jun | Wood Larry L | Global President TAVR & Surg | Disposed | S-Sale | 8950 |